News

New Immunology Panels from Immunosciences Lab

Immunosciences Lab., Inc. (ISL) is a pioneer and leader in the field of clinical immunology. Licensed in California and certified by both CLIA and the College of American Pathologists, ISL was founded in 1989 and has specialised in developing unique immunological assays that has earned the lab an international reputation. The research that went into the development of these tests has been published in the most prestigious medical journals in the field. The recognition by these respected publications and the many U.S. patents awarded to Immunosciences Lab., Inc. is testimony to ISL's over two decades of expertise and in-depth understanding of clinical immunopathology.

Lyme Disease
Borrelia burgdorferi, the infectious agent of Lyme disease, is another known factor associated with autoimmune diseases such as Lyme arthritis and neuroborreliosis. ISL’s patented Lyme Panel B, is the most sensitive assessment for Lyme disease and other tick-borne infections. Diagnosis of Lyme disease can be difficult because its symptoms share commonalities with ALF, Alzheimer's, autism, chronic fatigue syndrome, fibromyalgia, lupus, Parkinson's and RA. It is crucial to combine clinical symptomatology with the most sensitive techniques available to properly diagnose Lyme disease.

Viral Panels
Viruses, in particular, HHV-6, are some of the major contributing factors in autoimmunity, thus, the addition of HHV-6 IgG and IgM to EBV, CMV, HSV, VZV and Measles makes ISL’s viral assessments unique. Viruses can also affect the ability of T-cells to detect antigens by cross-reaction (molecular mimicry). If viral infections remain untreated, they may result in over-activation of the immune system, which may subsequently progress to autoimmune diseases. The addition of HHV-6 IgG and IgM to EBV, CMV, HSV, VZV and Measles makes ISL’s viral assessments unique.

The simultaneous detection of biomarkers of autoimmunity along with viral or Borrelia antibodies may assist the practitioner in pinpointing the cause and effect relationship of a disease, which can help to design an effective treatment.

Available Panels:
Viral Screen Essential

Biomarkers:

EBV Viral Capsid (VCA) IgG
EBV Viral Capsid (VCA) IgM 
Cytomegalovirus (CMV) IgG 
Cytomegalovirus (CMV) IgM
Herpes simplex Virus (HSV) 1+2 IgG 
Herpes simplex Virus (HSV) 1+2 IgM


Viral Screen Premier

Biomarkers:

EBV Viral Capsid (VCA) IgG
EBV Viral Capsid (VCA) IgM
EBV Early Antigen (EA) - D IgG
EBV Nuclear Antigen (EBNA) IgG 
EBV Nuclear Antigen (EBNA) IgM 
Cytomegalovirus (CMV) IgG 
Cytomegalovirus (CMV) IgM
Herpes simplex Virus (HSV) 1+2 IgG 
Herpes simplex Virus (HSV) 1+2 IgM 
Human Herpes Type 6 (HHV-6) IgG 
Human Herpes Type 6 (HHV-6) IgM 
Varicella zoster (VZV) IgG

Viral Screen Comprehensive

Biomarkers:

EBV Viral Capsid (VCA) IgG
EBV Viral Capsid (VCA) IgM
EBV Early Antigen (EA) - D IgG
EBV Nuclear Antigen (EBNA) IgG
EBV Nuclear Antigen (EBNA) IgM
Cytomegalovirus (CMV) IgG 
Cytomegalovirus (CMV) IgM
Herpes simplex Virus (HSV) 1+2 IgG
Herpes simplex Virus (HSV) 1+2 IgM
Human Herpes Type 6 (HHV-6) IgG
Human Herpes Type 6 (HHV-6) IgM
Varicella zoster (VZV) IgG
Rubeola (Measles) IgG
Rubeola (Measles) IgM
BV Viral Capsid (VCA) IgG
EBV Viral Capsid (VCA) IgM 
Cytomegalovirus (CMV) IgG 
Cytomegalovirus (CMV) IgM
Herpes simplex Virus (HSV) 1+2 IgG 
Herpes simplex Virus (HSV) 1+2 IgM

Immunoserology of Lyme

Biomarkers:

Borrelia burgdorferi (IgG, IgM) 
OspA + OspC Peptides (IgG, IgM)
OspE Peptide (IgG, IgM)
Leukocyte Function Associated Antigen (IgG, IgM)
Immunodominant Protein (IgG, IgM)
Variable Major Protein (IgG, IgM)
B. b. sensu stricto (IgG, IgM)
B. garinii (IgG, IgM)
B. afzelii (IgG, IgM)
Babesia (IgG, IgM)
Ehrlichia (IgG, IgM)
Bartonella (IgG, IgM)

Western Blot Assay
B. burgdorferi (IgG, IgM)

Epstein Barr Virus (EBV) Panel

Biomarkers:

EBV Viral Capsid (VCA) IgG 
EBV Viral Capsid (VCA) IgM
EBV Early Antigen (EA) - D IgG 
EBV Nuclear Antigen (EBNA) IgG 
EBV Nuclear Antigen (EBNA) IgM


Aristo Vojdani, PhD, MSc, CEO

ISL's founder is a professor of neuroimmunology at the Carrick Institute for Graduate Studies, a faculty member in the Dept. of Preventive Medicine at Loma Linda University, and a past associate professor at the Charles Drew/UCLA School of Medicine and Science. He obtained his M.Sc. and Ph.D. in the fields of microbiology and clinical immunology with postdoctoral studies in tumor immunology at UCLA.  His on-going research, spanning a 45-year career, focuses on the role of environmental triggers in complex diseases.

Professor Vojdani’s research and focus on predictive antibodies has resulted in the development of numerous antibody arrays for the detection of many autoimmune disorders. Of particular note are the arrays for autoimmune diseases that originate from the gut and manifest as attacks on the body’s own tissues or organs, including the brain. An owner of 15 US patents for laboratory assessments, Professor Vojdani has published more than 140 articles in scientific journals.

Aristo Vojdani, PhD, MSc, CEO

He is the CEO and Technical Director of Immunosciences Lab., Inc. in Los Angeles, CA, and sits on the editorial board of five scientific journals. In 2006, he was given the prestigious Herbert J. Rinkel Award by the American Academy of Environmental Medicine (AAEM) for excellence in teaching the techniques of environmental medicine. On November 7, 2009, he was given the Linus Pauling, PhD Award by the American College for Advancement in Medicine. And in October of 2012 he was given the F. R. Carrick Research Institute’s extremely distinguished Lifetime Achievement Award.

Invivo News
Despina Giannopoulou joins invivo

Despina Giannopoulou joins invivo

Welcoming Despina Giannopoulou to the Invivo Team
Invivo Sponsor Susie Goodall

Invivo Sponsor Susie Goodall

Invivo: proud supporters of Susie Goodall during the Golden Globe Race 2018.
PULS Cardiac Test

PULS Cardiac Test

Protein Unstable Lesion Signature (PULS) Cardiac Test - Know Your Risk